10-K/A: Biomerica Files 10-K/A Amendment, Focus on Governance

Biomerica, Inc. has filed an amendment to its 2026 Annual Report on Form 10-K, primarily to restate Part III items concerning directors, executive officers, corporate governance, and related matters, alongside new certifications.

Summary

• This filing is an amendment (10-K/A) to Biomerica, Inc.'s Annual Report for the fiscal year ended May 31, 2026.
• The amendment is primarily to restate Part III of the report, covering Directors, Executive Officers, Corporate Governance, Executive Compensation, Security Ownership, Related Transactions, and Accountant Fees.
• New certifications from the principal executive officer and principal financial officer are included.
• The filing details the composition of the Board of Directors, including new members and committee assignments.
• Information on executive compensation, including base salaries, stock awards, and employment agreements, is provided.
• Details regarding security ownership by major shareholders, directors, and executive officers are updated.
• Related party transactions, including a sale of investment and a private placement involving directors and officers, are disclosed.
• The company's compensation recovery policy, adopted in November 2023, is also referenced.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to its nature as an amendment to an annual report, indicating potential issues or necessary corrections, and the focus on corporate governance and capital structure rather than operational performance.

Positives

• The amendment provides updated information on corporate governance, including director and committee structures.
• Details on executive and independent director compensation are clarified.
• The filing includes updated information on security ownership, showing B. Riley Principal Capital, LLC as a significant shareholder (10%).
• The company has a compensation recovery policy in place to address accounting restatements.
• The Board of Directors has established Audit, Compensation, and Nominating and Corporate Governance Committees.
• Independent directors are identified and their independence is assessed against SEC and Nasdaq rules.
• The company has a Code of Business Conduct and Ethics applicable to all directors, officers, and employees.

Negatives

• The filing is an amendment to an annual report, suggesting that the original filing may have contained omissions or required corrections.
• Several Section 16(a) reports were filed late by executive officers and directors, indicating potential compliance issues.
• The resignation of the Chief Financial Officer, Gary Lu, on April 14, 2026, is noted, with forfeiture of unvested equity awards.
• A related-party promissory note of $500,000 to CEO Zackary Irani is outstanding, secured by an investment in Diagnosis S.A. which has not yet been transferred.
• The company's common stock market value as of November 28, 2025, was approximately $6.6 million, with a closing price of $2.37 per share.

Risks

• The issuance of preferred stock, while providing flexibility, could delay or prevent a change in control or adversely affect common stock holders.
• Delaware law (Section 203) prohibits business combinations with interested stockholders for three years.
• Charter and Bylaw provisions may deter hostile takeovers or changes in control.
• The company's compensation recovery policy could lead to recoupment of incentive-based compensation from executive officers in case of an accounting restatement.
• Late filings of Section 16(a) reports by insiders may indicate internal control weaknesses or compliance challenges.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding future financial performance. It focuses on corporate structure, governance, and past transactions.

Management Comments

• Stockholders may obtain a printed copy of the Code of Business Conduct and Ethics, free of charge, by writing to the Corporate Secretary of the Company at our principal executive offices.
• The Board believes that the adoption of the Compensation Recovery Policy is consistent with the Company's executive compensation philosophy and objectives, and in furtherance of the Board's intention to follow sound corporate governance practices.

Industry Context

StockSavvy.ai notes that this filing, being an amendment to an annual report and focusing on corporate governance and capital structure, provides less insight into the company's operational performance or market position compared to a standard earnings release. The details on director designations and private placements are common for companies seeking to strengthen their financial position or governance framework.

Management Changes

Corporate Governance

Legal Proceedings

• To the company's knowledge, during the past ten years, none of its directors or executive officers have been involved in any legal proceedings required to be disclosed pursuant to Item 401(f) of Regulation S-K.

Related Party Transactions

• On May 29, 2026, Biomerica sold its minority investment in Diagnosis S.A. to Zackary S. Irani (CEO and Director) and other purchasers for $500,000. A secured promissory note of $500,000 was issued to Mr. Irani, bearing 8% interest, maturing May 29, 2027, secured by the Diagnosis S.A. shares.
• In August 2026, Biomerica conducted a private placement where its CEO, directors, and other investors purchased shares. Zackary S. Irani purchased 31,250 shares for $50,000; Allen Barbieri purchased 20,000 shares for $32,000; Eric B. Chin purchased 6,250 shares for $10,000; Gary M. Huff purchased 31,250 shares for $50,000; and David Moatazedi purchased 10,000 shares for $16,000.

Stakeholder Impact

• Shareholders: The private placement at $1.60 per share could be dilutive if the market price is higher. The issuance of preferred stock could affect voting power and rights.
• Management and Employees: Equity awards are used to align interests, but the forfeiture of unvested equity by the former CFO may impact morale.
• Creditors: The outstanding promissory note to the CEO could impact liquidity if not resolved.
• Board of Directors: Changes in board composition and committee assignments affect oversight and decision-making.

Next Steps

• The company has filed a registration statement on Form S-3 to register the resale of shares purchased in the Private Placement.
• The company's Board of Directors will continue to oversee material risks, including financial, cybersecurity, and compliance risks.
• The Audit Committee will continue to monitor the integrity of financial processes and systems of internal controls.
• The Compensation Committee will continue to oversee management of risks relating to compensation plans and programs.
• The Nominating and Corporate Governance Committee will continue to assess the appropriate size of the Board and evaluate director candidates.

Key Dates

Recommendation

The filing is an amendment to an annual report, primarily addressing corporate governance and related party transactions rather than operational or financial performance. While the private placement indicates a need for capital, the terms and the participation of insiders suggest a focus on stabilizing the company. The late filings of Section 16(a) reports and the outstanding related-party note introduce some uncertainty. Without new financial performance data, a 'hold' recommendation is prudent, pending further operational updates.

Keywords

Corporate Governance, Directors, Executive Officers, Compensation, Stock Ownership, Related Party Transactions, Form 10-K/A, Biomerica